ADA Scientific Sessions 2026 Abstract

Safety, Tolerability, and Pharmacokinetic Characteristics of GZR102 Injection Compared with GZR4 or Bofanglutide

By Dongyang Liu, Fangfang Wang, Jing Zhao, Wei Chen

Trial in peopleInterventions

The paper

Dongyang Liu, Fangfang Wang, Jing Zhao, Wei Chen

Beijing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1805-P

doi.org/10.2337/db26-1805-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes